TP53 and head and neck squamous cell carcinoma: This finding is quite intriguing, knowing that inactivating TP53 mutations often confer intrinsic resistance towards CDK4/6i monotherapy in HNSCC and may also partially explain why abemaciclib is only rarely applied in this entity.